Robert Califf (Pablo Martinez Monsivais, AP Images)
November 24, 2021 10:06 AM ESTUpdated 10:43 AM
People
FDA+

FDA com­mish nom­i­nee's fi­nan­cial dis­clo­sures re­veal a vast web of in­dus­try ties. Will they mat­ter?

Zachary Brennan

Senior Editor

Pres­i­dent Biden’s nom­i­nee to run the FDA was hit with some tepid crit­i­cism back in 2016 for be­ing too cozy with the bio­phar­ma in­dus­try be­cause …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times